SNCA and Parkinson disease: In addition to these rare α-synuclein mutations, other posttranslational modifications of α-synuclein that have been described in PD patients, including phosphorylated, nitrated, oxidized, oligomeric, and dopamine-modified α-synuclein forms, also present altered CMA-degradation rates [63].